<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846871</url>
  </required_header>
  <id_info>
    <org_study_id>13-069</org_study_id>
    <nct_id>NCT01846871</nct_id>
  </id_info>
  <brief_title>Tivozanib for Recurrent Glioblastoma</brief_title>
  <official_title>A Phase II Study of Tivozanib in Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is a Phase II clinical trial, which tests the safety and effectiveness of
      an investigational drug to learn whether the drug works in treating a specific cancer.
      &quot;Investigational&quot; means that the study drug tivozanib is still being studied. It also means
      that the FDA has not yet approved tivozanib for your type of cancer.

      Tivozanib is an anti-angiogenesis medicine that fights different types of cancer by blocking
      the blood supply to the tumor, so that the tumor does not receive the nutrients it requires
      to grow.

      In this research study, we are looking to see what effects, good and bad, tivozanib will have
      on you and your disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you are willing to participate in this study, you will be asked to undergo some screening
      tests and procedures that confirm you are eligible. Many of these tests and procedures are
      likely to be part of regular cancer care and may be done even if it turns out taht you do not
      take part in the research study. If you have had some of these tests or procedures recently,
      they may or may not have to be repeated. The screening process may include the following: a
      medical history, mini-mental status exam, physical exam, performance status,
      electrocardiogram, blood tests, urine test. If these tests show that you are eligible to
      participate in the research study, you will begin the study treatment. If you do not meet the
      eligibility criteria, you will not be able to participate in this research study.

      If you take part in this research study, you will be given a study drug-dosing calendar for
      each treatment cycle. Each treatment cycle lasts 28 days (4 weeks) during which time you will
      be taking the study drug once daily for 3 weeks and then no study drug for the last week of
      each cycle. The diary will also include special instructions for taking the study drug.

      During all cycles you will have a physical exam and you will be asked questions about your
      general health and specific questions about any problems that you might be having and any
      medications you may be taking.

      Standard contrast-enhanced (CE) MRI scans will be done prior to all odd-numbered study
      cycles. Vascular MRI scans will be done prior to start of treatment, Day 1 of treatment and
      prior to all even-numbered cycles. These studies will be done in the Charlestown Navy Yard.

      We would like to keep track of your medical condition for up to 24 months after your last
      dose of study treatment. We would like to do this by calling you on the telephone once a year
      to see how you are doing. Keeping in touch with you and checking your condition every year
      helps us look at the long-term effects of the research study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Alive and Progression Free After 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the number of patients with recurrent glioblastoma (GBM) alive and progression free 6 months (PFR6) after start of tivozanib therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Related Serious Adverse Events</measure>
    <time_frame>From the start of treatment until disease progression, unacceptable toxicity, or death; median duration of approximately 2 months</time_frame>
    <description>The number of participants with serious adverse events deemed possibly, probably, or definitely related to treatment. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>From the start of treatment until the time of death, median duration of approximately 8 months</time_frame>
    <description>Overall survival is measured from the start of treatment until the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival</measure>
    <time_frame>From the start of treatment until death or progression, median duration of approximately 2 months</time_frame>
    <description>Progression free survival is measured as the amount of time from the start of treatment until the time of death or disease progression. Progressive disease was assessed using MacDonald Criteria
Progressive disease: Progressive neurologic abnormalities not explained by causes unrelated to tumor 40 progression (example: anti-epileptic drug or corticosteroid toxicity, electrolyte abnormalities, hyperglycemia, etc.) or a greater than 25% increase in the volume of the tumor by MRI scan. If neurologic status deteriorates on a stable or increasing dose of corticosteroids, or if new lesions appear on serial MRI scans, this will also be considered PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best RANO Criteria Response</measure>
    <time_frame>2 years</time_frame>
    <description>Best response as assessed by Response Assessment in Neuro-Oncology (RANO) criteria.
Complete response
disappearance of all enhancing disease
sustained for at least 4 weeks
stable/improved non-enhancing FLAIR/T2W lesions
no new lesions
no corticosteroids
clinically stable/improved
Partial response &gt;50% or more decrease of all measurable enhancing lesions
sustained for at least 4 weeks
no progression of non-measurable disease
stable/improved non-enhancing FLAIR/T2W lesions
no new lesions
stable/reduced corticosteroids
clinically stable/improved
Stable disease
does not qualify for complete response, partial response or progression
stable non-enhancing FLAIR/T2W lesions
stable or reduced corticosteroids
clinically stable
Progression &gt;25% or more increase in enhancing lesions despite stable/increasing steroid dose
increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumor causes
any new lesion
Clinical deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid Dosage</measure>
    <time_frame>2 years</time_frame>
    <description>The number of participants on steroids at baseline and the number of participants that increased or decreased their use of steroids during the course of treatment. Participants that required an increase and decrease in steroid use over the course of treatment were counted in both categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Volume</measure>
    <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
    <description>Change in volume of the tumor in cubic centimeters at the given time points as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Apparent Diffusion Coefficient (ADC)</measure>
    <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
    <description>Change in the the median ADC value from baseline at the given timepoints. Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Ktrans</measure>
    <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
    <description>Change in the the median Ktrans value from baseline at the given time points. The volume transfer constant (Ktrans) reflects the efflux rate of gadolinium contrast from blood plasma into the tissue extravascular extracellular space (EES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Oxygen Saturation</measure>
    <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
    <description>The change in relative O2 saturation from baseline to the given time points. Oxygen saturation is a relative measure of the concentration of oxygen that is dissolved or carried in a given medium as a proportion of the maximal concentration that can be dissolved in that medium.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Tivozanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivozanib</intervention_name>
    <arm_group_label>Tivozanib</arm_group_label>
    <other_name>AV-951</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed glioblastoma that has progressed based on imaging or surgery

          -  Measurable disease

          -  No more than 3 prior chemotherapy regimens

          -  Must have recovered from toxicity of prior therapy. An interval of at least 3 months
             must have elapsed since the completion of the most recent course of radiotherapy; at
             least 3 weeks since last non-nitrosourea containing chemotherapy regimen or
             molecularly targeted agent; at least 6 weeks since the completion of a nitrosourea
             containing chemotherapy regimen

          -  Life expectancy of at least 12 weeks

          -  Able to tolerate MRIs

          -  Willing to use adequate, highly effective contraception measures while on study and
             for at least 45 days after the last dose of study drug

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Major surgical procedure or significant traumatic injury within 28 days of starting
             therapy; or minor surgical procedure within 7 days

          -  Receiving other study agents

          -  Prior therapy with an anti-VEGF agent

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to tivozanib

          -  Receiving any medications or substances that are inhibitors or inducers of CYP450
             enzymes

          -  Significant cardiovascular disease

          -  Non-healing wound, bone fracture or skin ulcer

          -  Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other
             gastrointestinal condition with increased risk of perforation; abdominal fistula,
             gastrointestinal perforation or intra-abdominal abscess within 4 weeks prior to
             administration of first dose of study drug

          -  Uncontrolled intercurrent illness

          -  Significant thromboembolic or vascular disorders within 6 months prior to
             administration of first dose of study drug

          -  Significant bleeding disorders within 6 months prior to administration of first dose
             of study drug

          -  Currently active second primary malignancy

          -  HIV positive and on combination antiretroviral therapy

          -  Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that
             severely affects the absorption of study drugs, major resection of the stomach or
             small bowel, or gastric bypass procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Gerstner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>December 17, 2018</results_first_submitted>
  <results_first_submitted_qc>December 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <disposition_first_submitted>December 1, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 1, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 2, 2016</disposition_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth R. Gerstner, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tivozanib</title>
          <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tivozanib</title>
          <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="51" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Alive and Progression Free After 6 Months</title>
        <description>To determine the number of patients with recurrent glioblastoma (GBM) alive and progression free 6 months (PFR6) after start of tivozanib therapy</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive and Progression Free After 6 Months</title>
          <description>To determine the number of patients with recurrent glioblastoma (GBM) alive and progression free 6 months (PFR6) after start of tivozanib therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Related Serious Adverse Events</title>
        <description>The number of participants with serious adverse events deemed possibly, probably, or definitely related to treatment. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
        <time_frame>From the start of treatment until disease progression, unacceptable toxicity, or death; median duration of approximately 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Related Serious Adverse Events</title>
          <description>The number of participants with serious adverse events deemed possibly, probably, or definitely related to treatment. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <description>Overall survival is measured from the start of treatment until the time of death.</description>
        <time_frame>From the start of treatment until the time of death, median duration of approximately 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <description>Overall survival is measured from the start of treatment until the time of death.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="5.2" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-Free Survival</title>
        <description>Progression free survival is measured as the amount of time from the start of treatment until the time of death or disease progression. Progressive disease was assessed using MacDonald Criteria
Progressive disease: Progressive neurologic abnormalities not explained by causes unrelated to tumor 40 progression (example: anti-epileptic drug or corticosteroid toxicity, electrolyte abnormalities, hyperglycemia, etc.) or a greater than 25% increase in the volume of the tumor by MRI scan. If neurologic status deteriorates on a stable or increasing dose of corticosteroids, or if new lesions appear on serial MRI scans, this will also be considered PD.</description>
        <time_frame>From the start of treatment until death or progression, median duration of approximately 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival</title>
          <description>Progression free survival is measured as the amount of time from the start of treatment until the time of death or disease progression. Progressive disease was assessed using MacDonald Criteria
Progressive disease: Progressive neurologic abnormalities not explained by causes unrelated to tumor 40 progression (example: anti-epileptic drug or corticosteroid toxicity, electrolyte abnormalities, hyperglycemia, etc.) or a greater than 25% increase in the volume of the tumor by MRI scan. If neurologic status deteriorates on a stable or increasing dose of corticosteroids, or if new lesions appear on serial MRI scans, this will also be considered PD.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.5" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best RANO Criteria Response</title>
        <description>Best response as assessed by Response Assessment in Neuro-Oncology (RANO) criteria.
Complete response
disappearance of all enhancing disease
sustained for at least 4 weeks
stable/improved non-enhancing FLAIR/T2W lesions
no new lesions
no corticosteroids
clinically stable/improved
Partial response &gt;50% or more decrease of all measurable enhancing lesions
sustained for at least 4 weeks
no progression of non-measurable disease
stable/improved non-enhancing FLAIR/T2W lesions
no new lesions
stable/reduced corticosteroids
clinically stable/improved
Stable disease
does not qualify for complete response, partial response or progression
stable non-enhancing FLAIR/T2W lesions
stable or reduced corticosteroids
clinically stable
Progression &gt;25% or more increase in enhancing lesions despite stable/increasing steroid dose
increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumor causes
any new lesion
Clinical deterioration</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
        </group_list>
        <measure>
          <title>Best RANO Criteria Response</title>
          <description>Best response as assessed by Response Assessment in Neuro-Oncology (RANO) criteria.
Complete response
disappearance of all enhancing disease
sustained for at least 4 weeks
stable/improved non-enhancing FLAIR/T2W lesions
no new lesions
no corticosteroids
clinically stable/improved
Partial response &gt;50% or more decrease of all measurable enhancing lesions
sustained for at least 4 weeks
no progression of non-measurable disease
stable/improved non-enhancing FLAIR/T2W lesions
no new lesions
stable/reduced corticosteroids
clinically stable/improved
Stable disease
does not qualify for complete response, partial response or progression
stable non-enhancing FLAIR/T2W lesions
stable or reduced corticosteroids
clinically stable
Progression &gt;25% or more increase in enhancing lesions despite stable/increasing steroid dose
increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumor causes
any new lesion
Clinical deterioration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steroid Dosage</title>
        <description>The number of participants on steroids at baseline and the number of participants that increased or decreased their use of steroids during the course of treatment. Participants that required an increase and decrease in steroid use over the course of treatment were counted in both categories.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
        </group_list>
        <measure>
          <title>Steroid Dosage</title>
          <description>The number of participants on steroids at baseline and the number of participants that increased or decreased their use of steroids during the course of treatment. Participants that required an increase and decrease in steroid use over the course of treatment were counted in both categories.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On steroids at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased dosage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased dosage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tumor Volume</title>
        <description>Change in volume of the tumor in cubic centimeters at the given time points as compared to baseline</description>
        <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
        <population>Measurements were not available for all participants at pre-cycle 2 and pre-cycle 3</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (Baseline)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
          <group group_id="O2">
            <title>Tivozanib (Cycle 1 Day 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O3">
            <title>Tivozanib (Pre-cycle 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O4">
            <title>Tivozanib (Pre-cycle 3)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Volume</title>
          <description>Change in volume of the tumor in cubic centimeters at the given time points as compared to baseline</description>
          <population>Measurements were not available for all participants at pre-cycle 2 and pre-cycle 3</population>
          <units>Cubic Centimeters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.37" lower_limit="5.18" upper_limit="31.11"/>
                    <measurement group_id="O2" value="-2.012" lower_limit="-6.08" upper_limit="-0.79"/>
                    <measurement group_id="O3" value="-2.75" lower_limit="-5.68" upper_limit="3.19"/>
                    <measurement group_id="O4" value="-3.53" lower_limit="-18.28" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Apparent Diffusion Coefficient (ADC)</title>
        <description>Change in the the median ADC value from baseline at the given timepoints. Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue.</description>
        <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (Baseline)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
          <group group_id="O2">
            <title>Tivozanib (Cycle 1 Day 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O3">
            <title>Tivozanib (Pre-cycle 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O4">
            <title>Tivozanib (Pre-cycle 3)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Apparent Diffusion Coefficient (ADC)</title>
          <description>Change in the the median ADC value from baseline at the given timepoints. Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue.</description>
          <units>mm2/s</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0013" lower_limit="0.0011" upper_limit="0.0015"/>
                    <measurement group_id="O2" value="-0.00009" lower_limit="-0.00014" upper_limit="-0.00005"/>
                    <measurement group_id="O3" value="-0.00024" lower_limit="-0.00032" upper_limit="-0.00011"/>
                    <measurement group_id="O4" value="-0.00023" lower_limit="-0.0003" upper_limit="-0.00004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Ktrans</title>
        <description>Change in the the median Ktrans value from baseline at the given time points. The volume transfer constant (Ktrans) reflects the efflux rate of gadolinium contrast from blood plasma into the tissue extravascular extracellular space (EES)</description>
        <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (Baseline)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
          <group group_id="O2">
            <title>Tivozanib (Cycle 1 Day 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O3">
            <title>Tivozanib (Pre-cycle 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O4">
            <title>Tivozanib (Pre-cycle 3)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Ktrans</title>
          <description>Change in the the median Ktrans value from baseline at the given time points. The volume transfer constant (Ktrans) reflects the efflux rate of gadolinium contrast from blood plasma into the tissue extravascular extracellular space (EES)</description>
          <units>mL/min/100 mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" lower_limit="0.026" upper_limit="0.054"/>
                    <measurement group_id="O2" value="-0.01468" lower_limit="-0.025" upper_limit="-0.010"/>
                    <measurement group_id="O3" value="-0.024" lower_limit="-0.032" upper_limit="-0.022"/>
                    <measurement group_id="O4" value="-0.030" lower_limit="-0.045" upper_limit="-0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Oxygen Saturation</title>
        <description>The change in relative O2 saturation from baseline to the given time points. Oxygen saturation is a relative measure of the concentration of oxygen that is dissolved or carried in a given medium as a proportion of the maximal concentration that can be dissolved in that medium.</description>
        <time_frame>Baseline, Cycle 1 day 2, pre-cycle 2, pre-cycle 3 (1 cycle= 4 weeks)</time_frame>
        <population>One participants was not available for assessment for the cycle 1 day 2 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (Baseline)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
          </group>
          <group group_id="O2">
            <title>Tivozanib (Cycle 1 Day 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O3">
            <title>Tivozanib (Pre-cycle 2)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
          <group group_id="O4">
            <title>Tivozanib (Pre-cycle 3)</title>
            <description>1.5 mg daily for 3 weeks, with 1 week off.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Oxygen Saturation</title>
          <description>The change in relative O2 saturation from baseline to the given time points. Oxygen saturation is a relative measure of the concentration of oxygen that is dissolved or carried in a given medium as a proportion of the maximal concentration that can be dissolved in that medium.</description>
          <population>One participants was not available for assessment for the cycle 1 day 2 measurement</population>
          <units>proportion of possible O2 concentration</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.55" upper_limit="0.68"/>
                    <measurement group_id="O2" value="-0.057" lower_limit="-0.11" upper_limit="-0.00003"/>
                    <measurement group_id="O3" value="-0.0041" lower_limit="-0.060" upper_limit="0.063"/>
                    <measurement group_id="O4" value="-0.097" lower_limit="-0.12" upper_limit="-0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment until disease progression, unacceptable toxicity, or death; median duration of approximately 2 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tivozanib</title>
          <description>1.5 mg daily for 3 weeks, with 1 week off.
Tivozanib</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, cerumen in right ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, hearing loss in right ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, Intermittent hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, Hemanopsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, Retro Orbital pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Investigations - Other, SGOT elevated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Investigations - Other, SGPT elevated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Abducens nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, Altered Coordination (right)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, Cognitive Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, numbness right limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, Speech impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elizabeth Gerstner</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-8770</phone>
      <email>EGERSTNER@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

